Sansure Biotech Plans to Acquire 100% Equity of Zhongshan Haiji
January 14, 2025
Source: drugdu
33
Beijing Business News (Reporter Ding Ning) - On January 11, Sansure Biotech (688289) announced that the company intends to acquire 100% equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhongshan Haiji") for 807.5 million yuan. Sansure Biotech stated that Zhongshan Haiji has certain production capacity in the areas of recombinant proteins, peptide technology platforms, as well as overall industrial microbiology and synthetic biology, which can create a synergistic development with the company in the field of functional biomedicine products. In the future, the company will continue to leverage the strengths of both parties to provide technical support and collaborative innovation for the research projects related to growth hormones. Additionally, the expertise in diagnostics can offer necessary validation and feedback support for the ongoing optimization and iteration of growth hormone products.
https://finance.eastmoney.com/a/202501123294309388.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Deuterium hydrobromide remdesivir tablets have received routine approval from the National Medical Products Administration January 14, 2025
- Konya once again authorized to go abroad; Oral Simeglutide Tablets Fully Launched | Medical Early Reference January 14, 2025
- The first domestically produced one! Hengrui applies for another heavyweight drug to be listed on the market January 14, 2025
- One innovative medical device approved for market launch January 14, 2025
- Confident in China’s Economic Outlook and Development in China, Will Continue to Deepen Commitment to the Chinese Market January 14, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
